260 related articles for article (PubMed ID: 17268204)
1. Is Pseudomonas aeruginosa exotoxin A a good carrier protein for conjugate vaccines?
Pier GB
Hum Vaccin; 2007; 3(2):39-40; author reply 41. PubMed ID: 17268204
[No Abstract] [Full Text] [Related]
2. Preparation of recombinant atoxic form of exotoxin A from Pseudomonas aeruginosa.
Kaloshin AA; Isakov MA; Mikhailova NA; Vertiev JV
Bull Exp Biol Med; 2013 Jan; 154(3):346-50. PubMed ID: 23484197
[TBL] [Abstract][Full Text] [Related]
3. Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.
Tanomand A; Farajnia S; Najar Peerayeh S; Majidi J
Iran Biomed J; 2013; 17(1):1-7. PubMed ID: 23279828
[TBL] [Abstract][Full Text] [Related]
4. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
Weldon JE; Pastan I
FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of bacterial N-linked glycosylation to develop a novel recombinant glycoconjugate vaccine against Francisella tularensis.
Cuccui J; Thomas RM; Moule MG; D'Elia RV; Laws TR; Mills DC; Williamson D; Atkins TP; Prior JL; Wren BW
Open Biol; 2013 May; 3(5):130002. PubMed ID: 23697804
[TBL] [Abstract][Full Text] [Related]
6. [Production and properties evaluation of monoclonal antibodies against Pseudomonas aeruginosa exotoxin A].
Soldatenkova AV; Iakovleva IV; Gavrilova NV; Mikhaĭlova NA; Sviridova VV
Zh Mikrobiol Epidemiol Immunobiol; 2014; (1):30-5. PubMed ID: 24738291
[TBL] [Abstract][Full Text] [Related]
7. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: protectivity in murine model.
Safari Zanjani L; Shapouri R; Dezfulian M; Mahdavi M; Shafiee Ardestani M
World J Microbiol Biotechnol; 2019 Jun; 35(6):94. PubMed ID: 31187291
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A.
Burkhardt M; Reiter K; Nguyen V; Suzuki M; Herrera R; Duffy PE; Shimp R; MacDonald NJ; Olano LR; Narum DL
Vaccine; 2019 Sep; 37(38):5762-5769. PubMed ID: 30262247
[TBL] [Abstract][Full Text] [Related]
9. A multicomponent Pseudomonas aeruginosa vaccine consisting of toxoids of protease, elastase, exotoxin A and a common protective antigen (OEP). Application in patients with diffuse panbronchiolitis.
Homma JY; Tanimoto H
Antibiot Chemother (1971); 1987; 39():215-21. PubMed ID: 3118783
[No Abstract] [Full Text] [Related]
10. [Study of protective properties of recombinant atoxic form of exotoxin A and recombinant outer membrane protein F of Pseudomonas aeruginosa].
Mikhaĭlova NA; Vertiev IuV; Kaloshin AA; Isakov MA
Zh Mikrobiol Epidemiol Immunobiol; 2010; (2):39-44. PubMed ID: 20464999
[TBL] [Abstract][Full Text] [Related]
11. [Immunobiological properties of recombinant atoxic forms of the Pseudomonas aeruginosa exotoxin A].
Isakov MA; Soldatenkova AS; Kaloshin AA; Mikhaĭlova NA
Zh Mikrobiol Epidemiol Immunobiol; 2011; (2):37-42. PubMed ID: 21598613
[TBL] [Abstract][Full Text] [Related]
12. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
13. Host translational inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an immune response in Caenorhabditis elegans.
McEwan DL; Kirienko NV; Ausubel FM
Cell Host Microbe; 2012 Apr; 11(4):364-74. PubMed ID: 22520464
[TBL] [Abstract][Full Text] [Related]
14. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
[TBL] [Abstract][Full Text] [Related]
15. Clearance of Pseudomonas aeruginosa from normal rat lungs after immunization with somatic antigens or toxin A.
Johansen HK; Cryz SJ; Høiby N
APMIS; 1994 Jul; 102(7):545-53. PubMed ID: 7917224
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa exotoxin A antibodies in rapidly deteriorating chronic leg ulcers.
Danielsen L; Westh H; Balselv E; Rosdahl VT; Döring G
Lancet; 1996 Jan; 347(8996):265. PubMed ID: 8551911
[No Abstract] [Full Text] [Related]
17. Immunotoxins containing Pseudomonas exotoxin A: a short history.
Pastan I
Cancer Immunol Immunother; 2003 May; 52(5):338-41. PubMed ID: 12700949
[No Abstract] [Full Text] [Related]
18. A polyvalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.
Cryz SJ; Fürer E; Sadoff JC; Germanier R
Antibiot Chemother (1971); 1987; 39():249-55. PubMed ID: 3118786
[No Abstract] [Full Text] [Related]
19. [Antibody titers in the serum of patients vaccinated with the multicomponent vaccine consisting of toxoids of protease, elastase and a common protective antigen (OEP)].
Yamamoto M; Kubota Y; Matsuura M; Homma JY
Kansenshogaku Zasshi; 1986 Nov; 60(11):1178-83. PubMed ID: 3102639
[No Abstract] [Full Text] [Related]
20. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.
Shadman Z; Farajnia S; Pazhang M; Tohidkia M; Rahbarnia L; Najavand S; Toraby S
BMC Infect Dis; 2021 Mar; 21(1):300. PubMed ID: 33761869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
